Suprelorin
Active substance
ATC code
Species
Dogs (male) and ferrets (male).
Indications
For the induction of temporary infertility in healthy, entire, sexually mature male dogs and ferrets.
Dose to be administered and administration route
Dogs:
Subcutaneous use.
The recommended dose is one implant per dog, irrespective of the size of the dog (see also point 3.4). Disinfection of the implantation site should be undertaken prior to implantation to avoid introduction of infection. If the hair is long, a small area should be clipped, if required.
The veterinary medicinal product should be implanted subcutaneously in the loose skin on the back between the lower neck and the lumbar area. Avoid injection of the implant into fat, as release of the active substance might be impaired in areas of low vascularisation.
1. Remove Luer Lock cap from the implanter.
2. Attach the actuator to the implanter using the Luer Lock connection.
3. Lift the loose skin between the shoulder blades. Insert the entire length of the needle subcutaneously.
4. Fully depress the actuator plunger and, at the same time, slowly withdraw the needle.
5. Press the skin at the insertion site as the needle is withdrawn, and maintain pressure for 30 seconds.
6. Examine the syringe and needle to ascertain that the implant has not remained within the syringe or needle, and that the spacer is visible. It may be possible to palpate the implant in situ.
Repeat administration every 12 months to maintain efficacy.
Ferrets:
Subcutaneous use.
The recommended dose is one implant per ferret, irrespective of the size of the ferret.
Disinfection of the implantation site should be undertaken prior to implantation to avoid introduction of infection. If the hair is long, a small area should be clipped, if required.
It is recommended that the product should be administered under general anaesthesia in ferrets.
The product should be implanted subcutaneously in the loose skin on the back in the intrascapular space. Avoid injection of the implant into fat, as release of the active substance might be impaired in areas of low vascularisation.
1. Remove Luer Lock cap from the implanter.
2. Attach the actuator to the implanter using the Luer Lock connection.
3. Lift the loose skin between the shoulder blades. Insert the entire length of the needle subcutaneously.
4. Fully depress the actuator plunger and, at the same time, slowly withdraw the needle.
5. Press the skin at the insertion site as the needle is withdrawn, and maintain pressure for 30 seconds.
6. Examine the syringe and needle to ascertain that the implant has not remained within the syringe or needle, and that the spacer is visible. It may be possible to palpate the implant in situ. Tissue glue is recommended to close the site of administration if required.
The need for subsequent implantations should be based on the increase of testis size and/or increase in plasma testosterone concentrations as well as return to sexual activity. See also point 3.4.
Dogs and ferrets:
Do not use the veterinary medicinal product if the foil pouch is broken.
The biocompatible implant does not require removal. However, should it be necessary to end treatment, implants may be surgically removed by a veterinarian. Implants may be located using ultrasound.
Adverse reactions
Dogs:
Common (1 to 10 animals / 100 animals treated): | Implant site swelling1 |
Rare (1 to 10 animals / 10,000 animals treated): | Hair change (Hair loss, Alopecia, Hair modification) Urinary incontinence Reduced testicle size Decreased activity, Weight gain |
Very rare (<1 animal / 10,000 animals treated, including isolated reports): | Ascending testicle2, Increased testicle size3, Testicular pain3 Increased sexual interest3, Aggression4 Epileptic seizures5 |
1Moderate, for 14 days
2Through the inguinal ring
3Immediately following implantation, transitory, resolving without treatment
4Transient
5On average 40 days after implantation, median time to onset of signs was 14 days after implantation, on the same day of implantation at the earliest, and 36 weeks after implantation at the latest.
Ferrets:
Common (1 to 10 animals / 100 animals treated): | Implant site swelling1, Implant site pruritus1, Implant site erythema1 |
1Transient, moderate
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
